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ABSTRACT:
Insulin-like growth factor (IGF) signaling is thought to play a role in the development and progression of multiple cancer types. To date, therapeutic strategies aimed at disrupting IGF signaling have largely focused on antibodies that target the IGF-1 receptor. Here, we describe the pharmacologic profile of BI 836845, a fully human monoclonal antibody that utilizes an alternative approach to IGF signaling inhibition by selectively neutralizing the bioactivity of IGF ligands. Biochemical analyses of BI 836845 demonstrated high affinity to human IGF-1 and IGF-2, resulting in effective inhibition of IGF-induced activation of both IGF-1R and IR-A in vitro.
Cross-reactivity to rodent IGFs has enabled rigorous assessment of the pharmacologic activity of BI 836845 in preclinical models. Pharmacodynamic studies in rats showed potent reduction of serum IGF bioactivity in the absence of metabolic adverse effects, leading to growth inhibition as evidenced by reduced body weight gain and tail length. Moreover, BI 836845 reduced the proliferation of human cell lines derived from different cancer types and enhanced the antitumor efficacy of rapamycin by blocking a rapamycin-induced increase in upstream signaling in vitro as well as in human tumor xenograft models in nude mice. Our data suggest that BI 836845 represents a potentially more effective and tolerable approach to the inhibition of IGF signaling compared with agents that target the IGF-1 receptor directly, with potential for rational combinations with other targeted agents in clinical studies.
Introduction
Insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) are structurally related polypeptides that promote cell growth and survival (1) . In normal physiology, IGFs have key roles in the control of cellular proliferation and survival and of organism growth (2) . Their concentrations in blood are physiologically regulated and reflect hepatic production, but IGFs are also expressed locally in many tissues in a paracrine or autocrine manner (3) . Tissue IGF bioactivity varies not only with circulating ligand concentration and with local ligand production, but also with the concentrations of the various serum IGF-binding proteins (4;5).
IGF-1 signals by binding to the IGF-1 receptor (IGF-1R) or to hybrids of IGF-1R and
insulin receptors (InsR) (1;6). IGF-2 initiates signaling via these same receptor species, but can also activate the A isoform of the InsR (IR-A) (7;8) . This is of particular interest from an oncologic perspective as IR-A is preferentially expressed in fetal and cancer cells (9;10) . In contrast to members of the epidermal growth factor (EGF) family, which are frequently amplified and/or mutationally activated in neoplasia, resulting in ligand-independent receptor activation, IGF-1R/InsR signaling always requires active ligands.
More than a decade of preclinical research has provided a rationale for targeting IGF signaling in the treatment of cancer (1;11) . Oncogenic transformation of mouse embryonic fibroblasts, for instance, has been described to be dependent on the expression of IGF-1R (12) .
Expression of IGF-2 by transformed cells has been observed (13) and this can lead to activation of IGF-1R in an autocrine manner. In many preclinical cancer models, tumor growth can be stimulated by IGF-1 or IGF-2, and tumors grow substantially slower in mice carrying a mutation that reduces IGF ligand levels (4). Moreover, a separate line of indirect evidence for the relevance of IGF signaling for neoplasia comes from the observation that there is considerable interindividual variation in circulating IGF-1 levels, and that risk and prognosis of certain cancers is related to circulating IGF-1 concentration (2;14;15). Finally, IGF signaling may also play a role as a resistance mechanism which limits the effectiveness of cytotoxic or targeted anti-cancer agents, including rapalogs (16) (17) (18) (19) (20) (21) .
This preclinical evidence has motivated the development of several IGF-1 receptortargeted mAbs (22) (23) (24) . However, efficacy of anti-IGF-1R antibodies has been disappointing in clinical trials to date (25) (26) (27) (28) (29) (30) . One possible explanation for these results is that in clinical use, drugs studied to date do not adequately inhibit IGF signaling, especially in the context of the need to block autocrine loops in IGF-dependent cancers (31) (32) (33) , particularly those driven by IGF-2, which can also signal via IR-A (34) . For the alternative approach of targeting all receptor species in the insulin/IGF tyrosine kinase receptor family using small molecule inhibitors, the dosing of these agents must be well balanced to avoid metabolic toxicity and it remains to be demonstrated that clinical use at tolerable doses leads to adequate receptor blockade in neoplastic tissue.
A third therapeutic strategy is to target the IGF ligands rather than the receptors, aiming to abrogate signaling via IGF-1R and IR-A as well as their hybrid receptors, without impact on circulating insulin and glucose levels and their metabolic functions (30) . Two agents, BI 836845 and MEDI-573 (35) , with this mode of action have been developed. Here, we describe the pharmacological activity of BI 836845, a fully human monoclonal antibody that neutralizes the activities of both IGF-1 and IGF-2. In contrast to MEDI-573, BI 836845 cross-reacts with mouse and rat IGF-1 and IGF-2, allowing a comprehensive in vivo characterization of the pharmacodynamic properties of the antibody in preclinical rodent models.
Materials and Methods

Reagents and Cell Lines
BI 836845 was isolated by selection of specific Fab fragment clones from the human combinatorial antibody phage display library (HuCAL Gold) (36) that bind human IGF-1 with low nanomolar affinity, in three panning cycles as previously described (37) and subsequently subjected to in vitro affinity maturation (38) . IGF-1R antibodies used were αIR-3 (Calbiochem, No. GR11L) and one which was generated based on sequence ID 2. 1000 RU of a rabbit-anti-human Fc-gamma-specific antibody in flow cell 2 using reagents from an amine coupling kit. The test antibody was captured by running a 1 µg/mL solution over the sensor surfaces for 3 min. IGF antigens were diluted to 500, 250, 125, 62.5 and 31.3 nM and measured in random order using 5 min for association and dissociation. Data evaluation was performed using the BIAevaluation software, version 4.1. Biacore 3000 instrument; HBS-EP buffer, amine coupling kit and BIAevaluation software were provided by Biacore/GE Healthcare, Freiburg, Germany.
Cell-Based IGF-1R and IR-A Phosphorylation Assays
Mouse embryonic fibroblast cell lines derived from IGF-1R-deficient mice and engineered to overexpress human IGF-1R or human IR-A were used to measure IGF bioactivity, defined here as the ability of a sample (serum, plasma, cell culture media) to stimulate receptor phosphorylation as determined by ELISA. The cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated FBS, 1 mM sodium pyruvate, 0.075% sodium bicarbonate, non-essential amino acids (NEAA; Gibco), and 0.3 µg/mL puromycin at 37°C and 5% CO 2 . The ELISA was performed following standard procedures.
Briefly, 10,000 cells/well were seeded on 96-well plates followed by a 24-hour incubation. Cells were starved in medium with 0.5% FBS overnight before a dilution range of BI 836845 or IGF-1R antibodies was added to the cells, followed by either IGF-1 (20 ng/mL), IGF-2 (100 ng/mL) or a human serum pool (20%). Cells were incubated for 30 min at 37°C and 5% CO 2 Finally, the reaction was stopped by adding 1 M phosphoric acid and the absorbance was read using a photometer (OD 450 nm, OD 650 nm as reference).
Rat Studies
Six to eight week-old male rats (Crl:WI[Han]) were treated intravenously once weekly for 13 weeks with 20, 60, or 200 mg/kg of BI 836845 and compared to vehicle-treated animals. The treatment phase was followed by a 12-week recovery phase. Plasma samples were taken at time points prior to, during, and after treatment. Rat body weight was measured twice weekly throughout the study and tail length at the end of the treatment period.
Xenograft Studies
Tumors (< 100 mm Supplementary Table 2) , and determination of total rat serum IGF-1 levels and ex vivo IGF-1 bioactivity are described in the Supplementary Materials and Methods.
Additional Materials and Methods
2D cell viability assays, Western blot and qRT-PCR analyses (primers/probes listed in
Statistics
Statistical analysis was performed using the GraphPad Prism software (GraphPad Software Inc.). Control (pre-treatment or vehicle-treated animals) and treatment groups were compared in one-way analyses of variance (ANOVA) followed by a Tukey's post test if not indicated otherwise. (p) values of less than 0.05 (*), 0.01 (**) and 0.001 (***) were considered to be statistically significant.
Results
Biochemical Characterization of BI 836845
BI 836845 is a fully human monoclonal antibody selected from a naïve phage display library and affinity optimized for IGF-1 binding. As shown in Supplementary Table 1, surface plasmon resonance analysis demonstrated that in addition to the high affinity for human IGF-1 (0.07 nM) BI 836845 also shows high affinity for human IGF-2 (0.8 nM). BI 836845 was also shown to strongly cross-react with mouse and rat IGF-1 and IGF-2 (Supplementary Table 1 ). No binding to human insulin was detected at up to 100-fold higher antibody concentrations (data not shown).
In order to measure IGF bioactivity (IGF-1R or IR-A kinase activating activity) in serum, plasma, or cell culture media, we developed a cell-based assay utilizing mouse fibroblasts engineered to express human IGF-1R or IR-A, in which receptor phosphorylation can be quantified by ELISA. This assay was initially used to determine the potency and effectiveness of BI 836845 in neutralizing recombinant IGF-1 and IGF-2. As shown in Figure 1A and 1B, BI 836845 inhibited both IGF-1 (20 ng/mL) and IGF-2 (100 ng/mL) induced IGF-1R phosphorylation with an IC 50 of 90 ng/mL (0.6 nM) and 1120 ng/mL (7.5 nM), respectively. In the same assay, two IGF-1R mAbs were less effective with respect to IGF-1-induced activation and displayed only weak effects on IGF-2-induced activation with more than 30% of IGF-2-induced IGF-1R phosphorylation remaining even at an antibody concentration of 100 nM ( Figure 1B) . Figure 1C demonstrates that BI 836845 also potently inhibited IGF-2 (100 ng/mL)-induced IR-A activation with an IC 50 of 815 ng/mL (5.4 nM), unlike IGF-1R-targeted antibodies which had no effect.
When cell culture medium containing 20% human serum was used to stimulate receptor phosphorylation, this could be completely neutralized by BI 836845 with an IC 50 of 246 ng/mL (1.6 nM). By contrast, an IGF-1R-targeted antibody showed only partial inhibition of IGF bioactivity ( Figure 1D ).
Pharmacodynamic Effects of BI 836845 in Vivo
The cross-reactivity of BI 836845 to mouse and rat IGF-1 and IGF-2 has allowed a comprehensive preclinical characterization of the pharmacodynamic properties of the antibody in these species. Pharmacodynamic effects of BI 836845 were studied in 6 -8 week-old rats treated once weekly for 13 weeks with 20, 60, or 200 mg/kg of the antibody (last treatment on day 85). Treatment with BI 836845 at all doses levels was well tolerated and resulted in a clear reduction in plasma IGF bioactivity as determined ex vivo by the bioassay described above (Figure 2A ). These effects of BI 836845 on plasma IGF bioactivity were seen despite a corresponding increase in total IGF-1 plasma levels. Figure 2C ). To confirm that the effect of BI 836845 on body weight was due to a reduction in body growth, tail length was monitored. Figure 2D shows that there was a dosedependent reduction in tail length compared to vehicle controls on day 85 of the study. In addition to these findings, we noted that essentially all organ weights were reduced. Moreover, we observed a reduction in secondary spongiosa of bones, where IGF-1 is known to play an important role (39) (data not shown).
Antineoplastic Activity of BI 836845 in Cancer Models
BI 836845 was assayed for in vitro growth inhibitory activity in cancer-derived cell lines grown in 10% FBS. The proliferation of several cell lines derived from different cancer types, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), Ewing's sarcoma, and multiple myeloma, was found to be potently inhibited by BI 836845 (low nM EC 50 values; Table 1 
BI 836845 Enhances the Antineoplastic Efficacy of Rapamycin
Previous studies have shown improved efficacy when combining IGF-1R mAbs with rapamycin (41;42). We were therefore interested in assessing whether the combination of an IGF ligand-neutralizing antibody with rapamycin would be an effective antineoplastic strategy.
We therefore tested the combined effect of BI 836845 and rapamycin on the viability and signaling of two BI 836845-sensitive Ewing's sarcoma-derived cell lines, SK-ES-1 and RD-ES.
Cell viability studies in vitro demonstrated that the combination of BI 836845 and rapamycin was more potent and effective than either single agent at inhibiting proliferation of both cell lines (Figure 4A and 4C; p<0.001 at concentrations ≥ 12.33 and ≥ 0.1 nM, respectively). To investigate the molecular mechanism behind the improved efficacy seen when both agents were combined, we assessed AKT phosphorylation levels (serine 473; pAKT) as a biomarker reflecting the consequences of rapamycin-induced relaxation of an inhibitory feedback loop (43) . Figure 4B ) and RD-ES cells ( Figure 4D ) with 100 nM rapamycin resulted in increased pAKT compared with untreated cells. When BI 836845 was combined with rapamycin phosphorylation of AKT was inhibited, indicating that the feedback increase in pAKT in the presence of rapamycin is dependent on IGF ligand-driven signaling ( Figures 4B and 4D ).
Treatment of SK-ES-1 (
The inhibitory effects on cell proliferation of the combination versus each single agent were tested in 60 cancer cell lines (Supplementary Figure 2A) . In 13 out of 17 cell lines derived from different cancer types, the effects on proliferation were consistent with the effects on AKT phosphorylation (Supplementary Figure 2B ).
An RD-ES xenograft model was used to determine if the additive effects of BI 836845
and rapamycin seen in vitro could be recapitulated in vivo. The combination of BI 836845 (twice weekly, 100 mg/kg i.p.) and rapamycin (5 x weekly, 5 mg/kg i.p.) was more effective (TGI 93%) at inhibiting tumor growth than either single agent (rapamycin TGI 75%, BI 836845 TGI 53%) after 20 days of treatment ( Figure 5A ). Single agent treatments were significantly different from control treatment from day 6 onward (p < 0.05 for rapamycin and p < 0.01 for BI 836845 on day on December 6, 2013. © 2013 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 6), while combination treatment differed significantly from controls from day 3 onward (p < 0.05 on day 3). Differences between single agent treatments and combination treatment were statistically significant from day 8 onward (p < 0.05 on day 8). Further analyses of pAKT levels in the RD-ES tumors showed that rapamycin increased pAKT levels and that this increase could be inhibited by BI 836845 ( Figure 5B ). IGF bioactivity in the serum of RD-ES tumor-bearing mice was increased upon rapamycin treatment compared to control mice ( Figure 5C ). BI 836845 treatment alone, and in combination with rapamycin, completely inhibited IGF bioactivity in plasma ( Figure 5C ). To investigate the contribution of RD-ES tumors to the elevated levels of plasma IGF bioactivity, we treated non-tumor-bearing mice similarly and found that rapamycin induced a significant increase in plasma IGF bioactivity comparable to that seen in the RD-ES tumor-bearing mice ( Figure 5D ). 
synthesis and/or a decrease in VEGF clearance caused by complex formation between VEGF and the antibody (46) .
In human cancers, autocrine expression of IGF-1 or IGF-2 is not a rare event (2) . It is unlikely that this represents a random deregulation of gene expression. Rather, a malignant clone that expresses both a growth factor and its receptor will likely have a proliferative advantage that will be selected for. Thus, autocrine expression of IGF may indicate a cancer that is responsive to and/or dependent on IGF-1R activation (1). However, this does not necessarily imply that such tumors will be responsive to any particular IGF targeting strategy. Interruption of an autocrine loop in vivo requires a high drug concentration in the tumor, and it is conceivable that pharmacokinetic or tolerability issues may limit efficacy of IGF-targeting therapies even for the subset of cancers that depend on IGF stimulation. Therefore, it was of interest to observe that BI 836845 was capable of significantly inhibiting not only in vitro proliferation of IGFsecreting cell lines but also the in vivo growth of a colorectal cancer model that expresses high levels of IGF-2. Despite the important pharmacodynamic information that has been generated from the profiling of BI 836845 in rats and mice, the translational limitation of using rodent models for studying IGF physiology is that they express far less IGF-2 than humans (47) , and this needs to be taken into consideration when interpreting such studies in rodents. Interestingly, a similar effect was seen in a study using vascular smooth muscle cells (51) .
However, the precise definition of the mechanism by which rapamycin increases serum IGF bioacitvity requires additional investigation and is an active area of research. Similarly, the evaluation of angiogenesis and proliferation markers, such as CD34 and Ki67, will be important since enhanced anti-angiogenic effects may also play a role in explaining the improved efficacy of the combination (48) .
Despite the recent clinical setbacks with agents targeting the IGF-1R (30) , the data presented here support the differentiated therapeutic concept of IGF-1/2 ligand neutralization which warrants clinical investigation. Preclinical antiproliferative activity was observed with BI 836845 both in vitro and in vivo, and long term exposure at levels sufficient to abolish IGF serum bioactivity and strongly attenuate somatic growth was not associated with significant toxicity in rats. The results presented also provide clues that may be relevant to the design of phase II clinical trials. Presuming that dosing of BI 836845 will not be limited by toxicity, a crucial issue will be defining a phase II dose. Our preclinical studies have identified measurable pharmacodynamic endpoints such as serum IGF bioactivity that will be useful for defining the PK/PD relationship in humans. With regards to rational rather than arbitrary drug combinations, our findings indicate that co-administration of BI 836845 with rapalogs deserves consideration, and with respect to potential selection criteria for tumors that may be particularly responsive, autocrine expression of IGF-1 or IGF-2 may define a subpopulation of interest (52) . 
